VeNS for Type 2 Diabetes

"This investigation is enrolling 300 persons who are between 22 and 70 years of age with type 2 diabetes mellitus. To be considered, participants ought to have been on a stable dosage of fewer than three anti-diabetic medications for 90 days preceding enrolment as well as under the care of either an endocrinologist or hospitalist. Additionally, potential trialists must yield their informed consent prior to any activities related to the research, possess access to Wi-Fi, come within seven years from diagnosis at US sites (any time worldwide in non-US countries), and present HbA1c levels ranging from 6.5%–9"

"The study is available to those aged between 22 and 70. Those under 18 have 192 studies they may be eligible for, while 1103 are open to seniors over the age of 65."

"Affirmative. According to information on clinicaltrials.gov, the trial remains open for recruitment and was initially posted on May 21st 2021. The most recent alteration of the listing took place November 3rd 2022 and 300 individuals will be accepted across 7 sites."

"The primary endpoint of this 24-week trial is Standardized Incidence Ratio for all device related Serious Adverse Events. Meanwhile, secondary goals include a modification in cardiovascular medication (increase/decrease/no change), reduced HbA1c levels relative to lost weight and BMI changes over the assessment period; these outcomes will be evaluated by expert members of the research group."

"The details of the trial hosted on clinicaltrials.gov indicate that this study is currently recruiting participants. The trial was published online in May 2021 and recently updated in November 2022."

"Several locations are offering this trial, such as South Florida Research Organization in Medley, Nevada, Palm Research Center in Las Vegas, Virginia and Oviedo Medical Research in Oviedo, California."